Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

BGI Joins with Clearbridge BioMedics to Develop Liquid Biopsy in China

publication date: May 17, 2016
BGI, the Shenzhen "omics" company, has partnered with Singapore's Clearbridge BioMedics to distribute and develop its liquid biopsy product in greater China. CBB's ClearCell® FX1 product separates circulating tumor cells (CTC) from the blood. BGI intends to use its expertise, which stretches from genomics to trans-omics, to develop a product that provides clinical insights from a blood draw for clinical and research use, furthering personalized medicine. The machine adds to BGI's offerings in the clinical diagnostics market. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

ChinaBio® Events

 

China Showcase 2020

San Francisco, USA

January 12, 2020

ChinaBio Partnering Forum 2020

Suzhou, China

May 6-7, 2020